Assessment of Structural and Activity-related Contributions of Various PIM-1 Kinase Inhibitors in the Treatment of Leukemia and Prostate Cancer

Overview

Journal Mol Divers

Date 2024 Apr 20

PMID 38642309

Authors

Anushka Sharma

Rahul Dubey

Vikas Asati

Gurkaran Singh Baweja

Shankar Gupta

Vivek Asati

Affiliations

Soon will be listed here.

Abstract

One of the most perilous illnesses in the world is cancer. The cancer may be associated with the mutation of different genes inside the body. The PIM kinase, also known as the serine/threonine kinase, plays a critical role in the biology of different kinds of cancer. They are widely distributed and associated with several biological processes, including cell division, proliferation, and death. Aberration of PIM-1 kinase is found in varieties of cancer. Prostate cancer and leukemia can both be effectively treated with PIM-1 kinase inhibitors. There are several potent compounds that have been explored in this review based on heterocyclic compounds for the treatment of prostate cancer and leukemia that have strong effects on the suppression of PIM-1 kinase. The present review summarizes the PIM-1 kinase pathway, their inhibitors under clinical trial, related patents, and SAR studies of several monocyclic, bicyclic, and polycyclic compounds. The study related to their molecular interactions with receptors is also included in the present manuscript. The study may be beneficial to scientists for the development of novel compounds as PIM-1 inhibitors in the treatment of prostate cancer and leukemia.

References

Alizadeh A, Shiri S, Farsinejad S . Metastasis review: from bench to bedside. Tumour Biol. 2014; 35(9):8483-523. DOI: 10.1007/s13277-014-2421-z. View

Lai A, Pasea L, Banerjee A, Hall G, Denaxas S, Chang W . Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. BMJ Open. 2020; 10(11):e043828. PMC: 7674020. DOI: 10.1136/bmjopen-2020-043828. View

Kashyap M, Sinha R, Mukhtar M, Athar M . Epigenetic regulation in the pathogenesis of non-melanoma skin cancer. Semin Cancer Biol. 2020; 83:36-56. DOI: 10.1016/j.semcancer.2020.11.009. View

Rawla P . Epidemiology of Prostate Cancer. World J Oncol. 2019; 10(2):63-89. PMC: 6497009. DOI: 10.14740/wjon1191. View

Wang L, Lu B, He M, Wang Y, Wang Z, Du L . Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front Public Health. 2022; 10:811044. PMC: 8888523. DOI: 10.3389/fpubh.2022.811044. View

DOLL R, Peto R . The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981; 66(6):1191-308. View

Bostwick D, Burke H, Djakiew D, Euling S, Ho S, Landolph J . Human prostate cancer risk factors. Cancer. 2004; 101(10 Suppl):2371-490. DOI: 10.1002/cncr.20408. View

Li Z, Chen C, Wang J, Hsia E, Li W, Squires J . Neuroendocrine differentiation of prostate cancer. Asian J Androl. 2013; 15(3):328-32. PMC: 3739654. DOI: 10.1038/aja.2013.7. View

McCubrey J, Steelman L, Chappell W, Abrams S, Wong E, Chang F . Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2006; 1773(8):1263-84. PMC: 2696318. DOI: 10.1016/j.bbamcr.2006.10.001. View

10.

Shafi A, Yen A, Weigel N . Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 2013; 140(3):223-38. DOI: 10.1016/j.pharmthera.2013.07.003. View

11.

Haggman M, Macoska J, Wojno K, Oesterling J . The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol. 1997; 158(1):12-22. DOI: 10.1097/00005392-199707000-00004. View

12.

Cozzo A, Fuller A, Makowski L . Contribution of Adipose Tissue to Development of Cancer. Compr Physiol. 2018; 8(1):237-282. PMC: 5806627. DOI: 10.1002/cphy.c170008. View

13.

Fischerova D . Ultrasound scanning of the pelvis and abdomen for staging of gynecological tumors: a review. Ultrasound Obstet Gynecol. 2011; 38(3):246-66. DOI: 10.1002/uog.10054. View

14.

Ballard H . The hematological complications of alcoholism. Alcohol Health Res World. 1997; 21(1):42-52. PMC: 6826798. View

15.

Bibi N, Sikandar M, Ud Din I, Almogren A, Ali S . IoMT-Based Automated Detection and Classification of Leukemia Using Deep Learning. J Healthc Eng. 2020; 2020:6648574. PMC: 7732373. DOI: 10.1155/2020/6648574. View

16.

Guillaume T, Thepot S, Peterlin P, Ceballos P, Le Bourgeois A, Garnier A . Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Transplant Cell Ther. 2021; 27(10):839.e1-839.e6. DOI: 10.1016/j.jtct.2021.06.029. View

17.

Grey W, Rio-Machin A, Casado P, Gronroos E, Ali S, Miettinen J . CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia. Sci Transl Med. 2022; 14(650):eabn3248. PMC: 7612983. DOI: 10.1126/scitranslmed.abn3248. View

18.

Yuan T, Qi B, Jiang Z, Dong W, Zhong L, Bai L . Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade. Eur J Med Chem. 2019; 178:468-483. DOI: 10.1016/j.ejmech.2019.06.002. View

19.

Feliciano S, de Oliveira Santos M, Pombo-de-Oliveira M, de Aquino J, de Aquino T, Arregi M . Incidence and mortality of myeloid malignancies in children, adolescents and Young adults in Brazil: A population-based study. Cancer Epidemiol. 2019; 62:101583. DOI: 10.1016/j.canep.2019.101583. View

20.

Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat C, Balbin M . PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2010; 25(1):130-4. PMC: 3878659. DOI: 10.1038/leu.2010.247. View